468 related articles for article (PubMed ID: 18175781)
21. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
[TBL] [Abstract][Full Text] [Related]
22. Natural history of immunoglobulin A nephropathy and predictive factors of prognosis: a long-term follow up of 204 cases in China.
Lv J; Zhang H; Zhou Y; Li G; Zou W; Wang H
Nephrology (Carlton); 2008 Jun; 13(3):242-6. PubMed ID: 18221258
[TBL] [Abstract][Full Text] [Related]
23. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
24. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.
Hopkin RJ; Bissler J; Banikazemi M; Clarke L; Eng CM; Germain DP; Lemay R; Tylki-Szymanska A; Wilcox WR
Pediatr Res; 2008 Nov; 64(5):550-5. PubMed ID: 18596579
[TBL] [Abstract][Full Text] [Related]
25. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
[TBL] [Abstract][Full Text] [Related]
26. Blood pressure, proteinuria and nephropathy in Fabry disease.
Jain G; Warnock DG
Nephron Clin Pract; 2011; 118(1):c43-8. PubMed ID: 21071972
[TBL] [Abstract][Full Text] [Related]
27. The effects of angiotensin-converting enzyme gene polymorphism on the progression of immunoglobulin A nephropathy in Malaysian patients.
Draman CR; Kong NC; Gafor AH; Rahman AF; Zainuddin S; Mustaffa WM; Radzi AM; Shamsul AS
Singapore Med J; 2008 Nov; 49(11):924-9. PubMed ID: 19037561
[TBL] [Abstract][Full Text] [Related]
28. [Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].
Mignani R; Feriozzi S; Carraro G; Martinelli F; Cianciaruso B
G Ital Nefrol; 2009; 26(5):577-84. PubMed ID: 19802803
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of uncontrolled hypertension in patients with Fabry disease.
Kleinert J; Dehout F; Schwarting A; de Lorenzo AG; Ricci R; Kampmann C; Beck M; Ramaswami U; Linhart A; Gal A; Houge G; Widmer U; Mehta A; Sunder-Plassmann G
Am J Hypertens; 2006 Aug; 19(8):782-7. PubMed ID: 16876675
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
Talbot AS; Lewis NT; Nicholls KM
Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
[TBL] [Abstract][Full Text] [Related]
31. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
[TBL] [Abstract][Full Text] [Related]
32. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
33. GFR, proteinuria and circadian blood pressure.
Agarwal R; Light RP
Nephrol Dial Transplant; 2009 Aug; 24(8):2400-6. PubMed ID: 19251741
[TBL] [Abstract][Full Text] [Related]
34. The choice of estimating equations for glomerular filtration rate significantly affects the prevalence of chronic kidney disease in a multi-ethnic population during health screening.
Teo BW; Ng ZY; Li J; Saw S; Sethi S; Lee EJ
Nephrology (Carlton); 2009 Sep; 14(6):588-96. PubMed ID: 19712259
[TBL] [Abstract][Full Text] [Related]
35. Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain.
Marcén R; del Castillo D; Capdevila L; Fernandez-Fresnedo G; Rodrigo E; Cantarell C; Fernández-Rodriguez A; López-Oliva MO; Camps J; Aljama P; Ortuño J; Arias M
Transplantation; 2009 May; 87(9):1340-6. PubMed ID: 19424034
[TBL] [Abstract][Full Text] [Related]
36. Absence of cornea verticillata in hemizygotes of a novel mutation in fabry disease.
Huerva V; Martín M; Canto LM; Yagüe J
Cornea; 2008 Sep; 27(8):970-2. PubMed ID: 18724168
[TBL] [Abstract][Full Text] [Related]
37. Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
Trimarchi H; Canzonieri R; Schiel A; Politei J; Stern A; Andrews J; Paulero M; Rengel T; Aráoz A; Forrester M; Lombi F; Pomeranz V; Iriarte R; Young P; Muryan A; Zotta E
J Nephrol; 2016 Dec; 29(6):791-797. PubMed ID: 26842625
[TBL] [Abstract][Full Text] [Related]
38. Kidney transplantation in patients with Fabry disease.
Cybulla M; Walter KN; Schwarting A; Divito R; Feriozzi S; Sunder-Plassmann G;
Transpl Int; 2009 Apr; 22(4):475-81. PubMed ID: 19207191
[TBL] [Abstract][Full Text] [Related]
39. Screening for decreased renal function in taxi drivers in Tehran, Iran.
Mahdavi-Mazdeh M; Saeed Hashemi Nazri S; Hajghasemi E; Nozari B; Zinat Nadia H; Mahdavi A
Ren Fail; 2010 Jan; 32(1):62-8. PubMed ID: 20113268
[TBL] [Abstract][Full Text] [Related]
40. Screening of a population at risk of chronic kidney disease: analysis of factors associated with low eGFR and microalbuminuria.
Ležaić V; Dimković N; Peković GP; Bukvić D; Bajčetić S; Bontić A; Zec N; Pavlović J; Marinković J; Dukanović L
Ren Fail; 2011; 33(10):969-76. PubMed ID: 21929449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
